Background—Data from randomized trials has demonstrated the superiority of bivalirudin to
glycoprotein IIb/IIIa inhibitors plus heparin in patients undergoing primary percutaneous …

To assess the efficacy of the direct thrombin inhibitor bivalirudin relative to heparin during
contemporary coronary intervention, 1,056 patients who underwent elective or urgent …

Objective: To evaluate the safety and efficacy of bivalirudin based therapy among patients
undergoing percutaneous coronary intervention (PCI) for stable coronary artery disease in a …

A recent large-scale, randomized trial demonstrated the noninferiority of a strategy of
bivalirudin with provisional glycoprotein (GP) IIb/IIIa inhibition compared with routine GP …

Aims: Current recommendations on the use of bivalirudin in patients treated with
percutaneous coronary intervention (PCI) are mostly based on trials comparing bivalirudin …

Background The efficacy and safety of bivalirudin versus heparin in patients undergoing
percutaneous coronary intervention (PCI) 1 remains controversial in to date. Our meta …

Aims To evaluate the effectiveness and safety of bivalirudin as used in routine care.
Bivalirudin has been studied as an alternative to heparin plus glycoprotein IIb/IIIa inhibitor …

Recent clinical trials have shown that while bivalirudin exhibits similar efficacy with heparin,
it offers several advantages over heparin, such as a better safety profile. We aimed to …

Objective: This study evaluates outcomes with bivalirudin vs heparin in various patient
subgroups and the overall population during percutaneous coronary interventions (PCI) …

Background Despite several randomized controlled trials and meta-analyses, the ideal
anticoagulant for patients undergoing primary percutaneous coronary intervention (PCI) …